The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a https://bookmark-group.com/story6391394/retatrutide-vs-tirzepatide-a-comparative-analysis